117 related articles for article (PubMed ID: 18314132)
41. Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Turner MJ; Lamorte MJ; Chretien N; Havari E; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2013 Aug; 261(1-2):29-36. PubMed ID: 23759318
[TBL] [Abstract][Full Text] [Related]
42. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype.
Wing MG; Waldmann H; Isaacs J; Compston DA; Hale G
Ther Immunol; 1995 Aug; 2(4):183-90. PubMed ID: 9358610
[TBL] [Abstract][Full Text] [Related]
43. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
44. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Cheetham GM; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
[TBL] [Abstract][Full Text] [Related]
45. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
46. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.
Macor P; Tripodo C; Zorzet S; Piovan E; Bossi F; Marzari R; Amadori A; Tedesco F
Cancer Res; 2007 Nov; 67(21):10556-63. PubMed ID: 17975000
[TBL] [Abstract][Full Text] [Related]
47. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
49. CD52 is a molecular target in advanced systemic mastocytosis.
Hoermann G; Blatt K; Greiner G; Putz EM; Berger A; Herrmann H; Cerny-Reiterer S; Gleixner KV; Walz C; Hoetzenecker K; Müllauer L; Reiter A; Sotlar K; Sexl V; Valent P; Mayerhofer M
FASEB J; 2014 Aug; 28(8):3540-51. PubMed ID: 24760752
[TBL] [Abstract][Full Text] [Related]
50. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Greenwood J; Gorman SD; Routledge EG; Lloyd IS; Waldmann H
Ther Immunol; 1994 Oct; 1(5):247-55. PubMed ID: 7584499
[TBL] [Abstract][Full Text] [Related]
51. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
Ambrose LR; Morel AS; Warrens AN
Blood; 2009 Oct; 114(14):3052-5. PubMed ID: 19638623
[TBL] [Abstract][Full Text] [Related]
52. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Hu Y; Turner MJ; Shields J; Gale MS; Hutto E; Roberts BL; Siders WM; Kaplan JM
Immunology; 2009 Oct; 128(2):260-70. PubMed ID: 19740383
[TBL] [Abstract][Full Text] [Related]
53. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
54. Development and evaluation of a novel anti-colorectal cancer monoclonal antibody, WL5.
Liu J; Di G; Wu CT; Hu X; Duan H
Biochem Biophys Res Commun; 2013 Mar; 432(2):370-7. PubMed ID: 23376714
[TBL] [Abstract][Full Text] [Related]
55. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
Lifely MR; Hale C; Boyce S; Keen MJ; Phillips J
Glycobiology; 1995 Dec; 5(8):813-22. PubMed ID: 8720080
[TBL] [Abstract][Full Text] [Related]
56. ILEX oncology acquires CD52 diagnostic rights for Campath.
Expert Rev Mol Diagn; 2002 Nov; 2(6):525-6. PubMed ID: 12465444
[No Abstract] [Full Text] [Related]
57. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
Pulaski HL; Spahlinger G; Silva IA; McLean K; Kueck AS; Reynolds RK; Coukos G; Conejo-Garcia JR; Buckanovich RJ
J Transl Med; 2009 Jun; 7():49. PubMed ID: 19545375
[TBL] [Abstract][Full Text] [Related]
58. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
Dons EM; Raimondi G; Zhang H; Zahorchak AF; Bhama JK; Lu L; Ezzelarab M; Ijzermans JN; Cooper DK; Thomson AW
Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
[TBL] [Abstract][Full Text] [Related]
59. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
60. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.
Rafiq S; Cheney C; Mo X; Jarjoura D; Muthusamy N; Byrd JC
Leukemia; 2012 Jul; 26(7):1720-2. PubMed ID: 22333878
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
